Elshenawy Mohamed 4

What Happened

• Mohamed Elshenawy, Chief Technology Officer of Hims & Hers Health, Inc. (HIMS), was granted 376,222 restricted stock units (RSUs) on March 11, 2026. The grant is reported at a price of $0.00 (no cash exchanged) and is recorded as a derivative award on the Form 4.
• The RSUs represent a contingent right to receive one share of Class A common stock per RSU upon vesting; the filing reports no immediate transfer of shares or sale proceeds.

Key Details

• Transaction date: March 11, 2026; Form 4 filed March 13, 2026 (appears filed within the standard two-business-day window).
• Reported price: $0.00; reported amount: 376,222 RSUs (derivative award).
• Shares owned after the transaction: Not disclosed on the filing.
• Footnotes: F1 — each RSU equals the right to one share of Class A common stock. F2 — RSUs vest based on service over a 4-year period in substantially equal quarterly installments on March 15, June 15, September 15 and December 15, with the first vesting date on June 15, 2026.
• No indication of a 10b5-1 plan, tax withholding sale, or immediate cashless exercise in this filing.

Context

• RSU grants are compensation/retention awards and do not transfer stock ownership until vesting; they typically indicate alignment with company performance but are not the same signal as an open‑market purchase.
• The economic value to the insider will depend on HIMS’s share price when RSUs vest and convert to shares.